Medical Affairs Consultancy · New Zealand
Supporting pharmaceutical organisations to design and execute robust launch strategies — enabling credible scientific leadership with patients at the centre.
Founder & Principal
About
I am a Medical Doctor with over 10 years' experience in Medical Affairs, combining clinical expertise with postgraduate training in Medicines Development and Public Health.
My work spans pre-launch, peri-launch, and early post-launch Medical Affairs strategy and execution — translating evidence into impactful medical plans that place patients at the centre of every decision.
I partner with pharmaceutical organisations navigating multiple markets, including New Zealand, bringing hands-on knowledge of local governance, funding-body access pathways, and the clinical dialogue required to support confident, ethical launch execution.
I also work with Arindam Bose at Aesculytics — he does the in silico trial and digital-twin modelling, I look at whether that evidence stacks up against the specific funding pathway you're going for (MolDX, NICE, MSAC, PHARMAC — they all want different things). Together that's A²I. Point of it is simple: you find out where your evidence is weak before you've designed the study, not after.
Services
I work with pharmaceutical organisations at the moments that define launch success — from strategy design through to post-launch optimisation.
Launch-ready Medical Affairs strategy and integrated planning aligned to global objectives, New Zealand governance, and local clinical and access pathways.
Enquire →Evidence-led scientific engagement and advisory boards aligned to launch milestones, generating actionable insight to inform confident, real-time launch decisions.
Enquire →Field medical enablement and ongoing execution support through launch and the first year post-launch, optimising impact as clinical practice and access evolve.
Enquire →Expertise
I combine clinical insight with business acumen to design Medical Affairs strategies that are both scientifically rigorous and commercially aligned — always with patients as the anchor of every decision.
Integrated medical plans aligned to therapeutic area evidence, HCP needs, and funding access requirements.
Credible external engagement including advisory boards, KOL relationships, and evidence generation planning.
Medical Affairs contribution to access, PHARMAC pathways, and guideline positioning in the NZ environment.
Equipping MSL teams and field medical functions for credible, evidence-based scientific exchange at launch.
Launch Phase Coverage
"My work focuses on translating evidence into impactful execution that places patients at the centre — contributing to guidelines, recommendations, access and funding considerations with the ultimate aim of positively influencing patient outcomes."
— Dr Alia Mahgoub, FounderCollaboration
Evidence generation to funding approval — explore the joint platform combining access strategy with in-silico evidence generation.
View Collab PageContact
Reach out to explore how Ascentra Medical can support your Medical Affairs strategy — whether you're planning a New Zealand launch, building your scientific engagement programme, or need senior medical leadership at a pivotal moment.